Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


The impact of obesity on treatment choices and outcomes in operable breast cancer.

Burkheimer E, Starks L, Khan M, Oostendorp L, Melnik MK, Chung MH, Wright GP.

Am J Surg. 2019 Mar;217(3):474-477. doi: 10.1016/j.amjsurg.2018.10.048. Epub 2018 Nov 14.


Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD.

JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.


Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.

Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR.

Oncotarget. 2016 Oct 25;7(43):69903-69915. doi: 10.18632/oncotarget.12065.


Measuring the impact of the American College of Surgeons Oncology Group Z0011 trial on breast cancer surgery in a community health system.

Wright GP, Mater ME, Sobel HL, Knoll GM, Oostendorp LD, Melnik MK, Chung MH.

Am J Surg. 2015 Feb;209(2):240-5. doi: 10.1016/j.amjsurg.2014.07.001. Epub 2014 Aug 20.


Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas.

Paul Wright G, Davis AT, Koehler TJ, Melnik MK, Chung MH.

Ann Surg Oncol. 2014 Oct;21(11):3497-503. doi: 10.1245/s10434-014-3782-7. Epub 2014 May 17.


Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors.

Mustian KM, Sprod LK, Janelsins M, Peppone LJ, Palesh OG, Chandwani K, Reddy PS, Melnik MK, Heckler C, Morrow GR.

J Clin Oncol. 2013 Sep 10;31(26):3233-41. doi: 10.1200/JCO.2012.43.7707. Epub 2013 Aug 12.


MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.


Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.


Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.

Melnik MK, Webb CP, Richardson PJ, Luttenton CR, Campbell AD, Monroe TJ, O'Rourke TJ, Yost KJ, Szczepanek CM, Bassett MR, Truszkowski KJ, Stein P, Van Brocklin MW, Davis AT, Bedolla G, Vande Woude GF, Koo HM.

Mol Cancer Ther. 2010 Aug;9(8):2423-9. doi: 10.1158/1535-7163.MCT-09-0854. Epub 2010 Aug 3.


Malignant melanoma in childhood and adolescence.

Melnik MK, Urdaneta LF, Al-Jurf AS, Foucar E, Jochimsen PR, Soper RT.

Am Surg. 1986 Mar;52(3):142-7.


Supplemental Content

Loading ...
Support Center